Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 35.95% is in line with its 5-year average of 36.55%, around the middle of its 5-year range (19.60%–57.81%).
2.36% below its 12-month average of 36.82%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 40.90%.
GROSS MARGIN
35.95%
GROSS MARGIN AVG TTM
36.82%
GROSS MARGIN AVG 3Y
34.81%
GROSS MARGIN AVG 5Y
36.55%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-2.36%
CURRENT VS 3Y AVG
+3.26%
CURRENT VS 5Y AVG
-1.64%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 784 covered companies
CURRENT VS SECTOR MEDIAN
-11.52%
vs the sector median at left
Market Cap
$10.06M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$9.76M
Gross Margin
-3767.20%
TTM Avg
-1960.46%
3Y Avg
-1022.20%
5Y Avg
-664.64%
Market Cap
$9.70M
Gross Margin
67.30%
TTM Avg
49.28%
3Y Avg
20.15%
5Y Avg
20.34%
Market Cap
$10.33M
Gross Margin
-16431.82%
TTM Avg
-8215.91%
3Y Avg
-4057.95%
5Y Avg
-2671.97%
Market Cap
$10.42M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$9.36M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lifeward Ltd. (LFWD) | $9.92M | 35.95% | 36.82% | 34.81% | 36.55% |
| MetaVia Inc. (MTVA)vs › | $9.88M | 0.00% | 0.00% | 0.00% | 0.00% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | 0.00% | 0.00% | 0.00% | 0.00% |
| Ainos, Inc. (AIMD)vs › | $9.76M | -3767.20% | -1960.46% | -1022.20% | -664.64% |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.70M | 67.30% | 49.28% | 20.15% | 20.34% |
| Polyrizon Ltd. (PLRZ)vs › | $10.32M | N/A | 0.00% | 0.00% | 0.00% |
| Senti Biosciences, Inc. (SNTI)vs › | $10.33M | -16431.82% | -8215.91% | -4057.95% | -2671.97% |
| Satellos Bioscience Inc. (MSLE)vs › | $10.42M | 0.00% | 0.00% | 0.00% | 0.00% |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.36M | 0.00% | 0.00% | 0.00% | 0.00% |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.51M | N/A | -101.19% | -33.23% | -22.16% |
Gross Margin
36.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 40.90% |
| 2026-03-31 | 34.21% |
| 2025-12-31 | 21.41% |
| 2025-09-30 | 43.70% |
| 2025-06-30 | 43.87% |
| 2025-03-31 | 42.15% |
| 2024-12-31 | 24.44% |
| 2024-09-30 | 36.23% |
| 2024-06-30 | 41.11% |
| 2024-03-31 | 26.41% |
| 2023-12-31 | 35.49% |
| 2023-09-30 | 19.60% |
| 2023-06-30 | 43.08% |
| 2023-03-31 | 46.42% |
| 2022-12-31 | 30.89% |
| 2022-09-30 | 24.94% |
| 2022-06-30 | 47.52% |
| 2022-03-31 | 30.25% |
| 2021-12-31 | 26.49% |
| 2021-09-30 | 57.81% |
| 2021-06-30 | 50.63% |
